From 19 to 21 May 2026, OphtAI will be exhibiting at the SANTEXPO trade fair at Paris Expo – Porte de Versailles, on the Evolucare stand (no. R46).
During the event, the team will present their artificial intelligence solution for the screening of retinal conditions, designed to address current public health challenges.
Artificial intelligence is transforming ophthalmological screening
Faced with the rise in chronic eye conditions such as diabetic retinopathy, glaucoma and AMD, healthcare systems are confronted with a twofold challenge: detecting conditions earlier and making the best use of available medical resources.
In this context, artificial intelligence is emerging as a key enabler. Through the automated analysis of retinal images, it now makes it possible to:
- achieve performance levels comparable to those of human experts,
- standardise the interpretation of examinations,
- roll out large-scale screening strategies,
- improve the organisation of care pathways.
AI is thus becoming a key tool for enhancing the effectiveness of screening whilst facilitating access to care, particularly in areas with a shortage of specialists.
OphtAI: proven technology for healthcare professionals
OphtAI is fully aligned with this drive for innovation. Developed using hundreds of thousands of images annotated by expert retinologists, the solution can automatically detect the main retinal conditions in a matter of seconds.
Its key capabilities include:
- detection of diabetic retinopathy, glaucoma and AMD,
- assessment of image quality,
- identification and localisation of lesions (heatmap-style mapping),
- indication of confidence levels and predictive values,
- generation of a detailed PDF report with medical recommendations.
AI that enhances clinicians’ capabilities
OphtAI’s aim is not to replace healthcare professionals, but to enhance their analytical and decision-making capabilities.
Combining human expertise with algorithmic intelligence makes it possible to:
- reduce the risk of error,
- identify early warning signs that are difficult to detect,
- improve the accuracy of clinical decisions.
This approach is part of a responsible vision of innovation: AI serving both practitioners and patients.
A driver of organisational efficiency
Beyond its diagnostic capabilities, OphtAI offers a practical solution to the organisational challenges faced in the field.
In particular, the solution enables:
- an initial automated review of images,
- sorting of cases by severity,
- prioritisation of high-risk patients,
- significant time savings for medical staff.
Whether integrated directly into information systems or accessed via a standard web browser, OphtAI fits seamlessly into existing workflows without adding complexity.
This automation allows ophthalmologists to focus on complex cases and high-value procedures, whilst ensuring comprehensive and secure screening.
Expertise drawn from an ecosystem of excellence
OphtAI is the result of a collaboration between industry, researchers and clinicians, notably with the AP-HP and INSERM. This synergy has enabled the creation of a unique database containing several hundred thousand retinal images.
This expertise is based on:
- over 30 years’ experience in healthcare data management,
- strong R&D capabilities (40% of the teams),
- a position amongst the leading players in healthcare AI in Europe.
Take action
Would you like to find out more about AI-powered screening solutions in ophthalmology and discover how to optimise your patient care pathways?
SANTEXPO is a must-attend event for professionals in the healthcare and innovation sectors. OphtAI’s presence at the Evolucare stand will provide an opportunity to:
- see the solution in action,
- discuss matters with industry and technical experts,
- and explore practical use cases in healthcare settings or in teleophthalmology.
📍 Venue: Paris Expo – Porte de Versailles
📅 Dates: 19–21 May 2026
📌 Stand: Evolucare – R46